BMS-986506 Clinical Trials (2026): 1 Studies for Renal Cell Carcinoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 BMS-986506 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Renal Cell Carcinoma) and 125 total planned enrollment. 1 BMS-986506 clinical trial is actively recruiting at 5 U.S. sites across 5 states. Most recent activity: NCT07195682 (Apr 2031).
Where to Participate: All BMS-986506 Trial Sites in the U.S. (5 sites across 5 states)
Every actively recruiting BMS-986506trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT07195682 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT07195682 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT07195682 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT07195682 | Map |
| TX | START San Antonio | San Antonio78229 | NCT07195682 | Map |
BMS-986506 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting BMS-986506 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07195682 | A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | P1 | Renal Cell Carcinoma | 125 | Jan 2026 |
All BMS-986506 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07195682 | A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | P1 | recruiting | 125 | Bristol-Myers Squibb | Jan 2026 |
BMS-986506 clinical trials: frequently asked questions
- How many BMS-986506 clinical trials are there?
- 1 BMS-986506 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are BMS-986506 clinical trials recruiting in 2026?
- Yes — 1 BMS-986506 trial is actively recruiting in 2026, with 5 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is BMS-986506 being studied for?
- BMS-986506 is being studied for Renal Cell Carcinoma. The trials are grouped by indication on this page.
- What phase is BMS-986506 in?
- BMS-986506 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors BMS-986506 clinical trials?
- The lead sponsor across the most BMS-986506 trials is Bristol-Myers Squibb. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming BMS-986506as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: